Tune Therapeutics Moves into Clinical Spotlight with TUNE-401: A First-in-Class Epigenetic Silencer for Hepatitis B

TUNE-401 will be the first epigenetic therapy to enter clinical trials for an infectious disease DURHAM, NC and SEATTLE, WA (November 14, 2024) – Leading epigenome editing company Tune Therapeutics announced today that it has received clinical trial application (CTA) approval from the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) to initiate a Phase 1b clinical […]